Login to Your Account

Sepsis Fells Another Contender

Agennix's Phase II/III Study Halted by Mortality Finding

By Nuala Moran
Staff Writer

Friday, February 3, 2012
LONDON – The challenging indication of severe sepsis has confounded yet another attempt to develop a registered treatment, with the curtailment of the Phase II/III trial of Agennix AG's talactoferrin.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription